Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

Texas MPN Workshop 2021 | Future treatment strategies for MPNs

Srdan Verstovsek • 23 Aug 2021

Texas MPN Workshop 2021

Essential Thrombocythemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases Ropeginterferon alfa-2b

Srdan Verstovsek, MD, The University of Texas, MD Anderson Cancer Center, Houston, TX, discusses what the future may hold with regards to treatment strategies for myeloproliferative neoplasms (MPNs). For essential thrombocythemia and polycythemia vera, Dr Verstovsek talks on the use of ropeginterferon, and for myelofibrosis Dr Verstovsek outlines the benefits of JAK inhibitor use, novel drugs to target anemia and new combinations and approaches with JAK inhibitors. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.

An update on the use of navtemadlin in myelofibrosis

Srdan Verstovsek • 7 Dec 2022

Insights into the Phase IIa Mylox-1 trial: assessing efficacy of GB2064 in myelofibrosis

Srdan Verstovsek • 7 Dec 2022

FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement

Srdan Verstovsek • 7 Dec 2022

Rationale for VERIFY: rusfertide added to ongoing therapy in patients with polycythemia vera

Srdan Verstovsek • 7 Dec 2022

Related Videos

Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH

Carlo Dufour • 15 Apr 2024

Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting

Alex Rampotas • 16 Apr 2024

Personalized risk assessment for transplantation in primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024

Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders

Thomas Fox • 15 Apr 2024